Precision Biologics to Unveil In Vitro and In Vivo Efficacy of New ADC against human ovarian cancer at AACR Special Conference

BETHESDA, Md., Sept. 19, 2025 /PRNewswire/ -- Precision Biologics, Inc. reports that in vitro and in vivo efficacy of the novel ADC, using its anti-core 2 O-glycans anti-human carcinoma mAb PB-223 (PB-vcMMAE-5), against human ovarian cancer expressing truncated core 2 O-glycans will be...